Behavioral modifications like goal setting could lead to greater weight loss on tirzepatide
Tuesday, June 16 – One of the largest real-world studies of people taking GLP-1 medications found women, those without pre-existing conditions such as type 2 diabetes and high blood pressure, and behavioral factors such as previously setting a weight goal were the best predictors of total weight loss, according to a study presented at ENDO 2026, the Endocrine Society’s annual meeting in Chicago.
Tirzepatide may change how the body uses energy, trial suggests
Tuesday, June 16 – Tirzepatide doesn’t just help people lose weight; it also activates brown adipose tissue, representing a major milestone in obesity research, according to a study presented at ENDO 2026, the Endocrine Society’s annual meeting in Chicago.
Diabetes Patients on Semaglutide Had Fewer Fractures, Study Finds
Tuesday, June 16 – (MedPage Today) — CHICAGO — The GLP-1 receptor agonist semaglutide (Ozempic, Wegovy) was associated with a 15% lower risk for fractures in adults with type 2 diabetes, a review of medical records found.
In a matched analysis involving more…
Apitegromab Preserves Lean Mass When Combined With Tirzepatide
MONDAY, June 15, 2026 — Selective targeting of myostatin by apitegromab preserves lean mass when combined with tirzepatide, according to a study published online June 8 in Nature Medicine.
Richard E. Pratley, M.D., from the AdventHealth…
ENDO: GLP-1 Receptor Agonists Tied to Higher Hypotension Risk in Patients on BP Meds
MONDAY, June 15, 2026 — Among patients with preexisting hypertension taking antihypertensive medications, glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with an increase in hypotensive-related events, according to a study…
Tirzepatide GLP-1 medication may be most effective for weight loss
Monday, June 15 – GLP-1 medications are marketed to help you lose weight, but one may be better at it than the rest, according to a new meta-analysis from the University of Georgia.
Clinical trials suggest GLP-1s may improve fertility in men with obesity
Monday, June 15 – GLP-1s do not harm male hormones or fertility after long-term use, according to a study being presented Monday at ENDO 2026, the Endocrine Society’s annual meeting in Chicago. In fact, the research team found GLP-1s may improve testosterone levels and sperm quality in men with obesity-related low testosterone, while also addressing the underlying effects of obesity.
GLP-1s may aid bone health as well as weight loss in type 2 diabetes
Tuesday, June 16 – GLP-1s may aid bone health as well as weight loss in type 2 diabetes.
How GLP-1 Weight Fluctuations Are Driving Up Clothing Returns
Monday, June 15 – Popular weight loss drugs, including Ozempic and Wegovy, have already transformed how people shop for food. Now, they’re impacting the way users buy their clothes as they slim down. But with so many shoppers uncertain about their fit and size, retailers are seeing a surge in returns that’s proving to be very costly. NBC’s Emilie Ikeda reports for TODAY.
Many Patients Stop And Restart GLP-1 Meds, Study Finds
MONDAY, June 15, 2026 — Folks are told that once you start taking Ozempic or Zepbound, you’ll need to stay on them to maintain the drugs’ benefits.
But patients prescribed such GLP-1 drugs are more likely to stop them and then…